We have demonstrated that the RXR agonist bexarotene, which has recently been shown to promote remyelination in individuals with MS has immunomodulatory effects on human cells - promoting naive CD4+ T-cell differentiation into Tregs and suppressing their differentiation into Th17 cells. Here, CD4 is linked to myeloid sarcoma.